Drugs / VXA-GI.1-NN
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04854746 Comparator | Apr 2021 → Jan 2022 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-GI.1-NN | “VXA-GI.1-NN tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log10” NCT04854746 ↗ |
| Modality | Vaccine | “adenoviral-vector based oral norovirus vaccine” NCT04854746 ↗ |
| Route | Oral | “administered orally” NCT04854746 ↗ |